R1 RCM — Q1 2022 Earnings Presentation
12 slides from R1 RCM's earnings presentation, May 9, 2022
Slide 1: First Quarter 2022 Earnings Call
May 9, 2022 First Quarter 2022 Earnings Call NEED NEW IMAGE THAT WE SENT Exhibit 99.2
Slide 2: Forward-Looking Statements
2 Forward-Looking Statements This presentation includes information that may constitute “forward-looking statements” made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995 and Section 21E of the Securities Exchange Act of 1934, as amended. Forward-looking
Slide 3: Disclaimer: Additional Information and Where to Find It
3 Disclaimer Additional Information and Where to Find It This presentation includes information regarding the proposed transaction between R1 and Cloudmed, a leader in Revenue IntelligenceTM solutions for healthcare providers. This presentation does not constitute an offer to sell or exchange, or th
Slide 4: Disclaimer: Financial Projections
4 Disclaimer Financial Projections All financial projections in this presentation are forward-looking statements that are based on assumptions that are inherently subject to significant uncertainties and contingencies, many of which are beyond R1’s control. No independent registered public accountin
Slide 5: First Quarter 2022 Results and Financial Outlook
5 First Quarter 2022 Results and Financial Outlook Revenue of $385.7 million, up $43.1 million or 12.6% compared to the same period last year GAAP net income of $29.4 million, up $3.6 million or 14.0% compared to the same period last year Adjusted EBITDA of $89.3 million, up $8.9 million or 11
Slide 6: Commercial and Operational Update
6 Commercial and Operational Update Negotiations with customer are complete with economic terms agreed to and governance process concluded Open item: Provisioning user access for our employees with a third-party vendor We remain very confident in getting the deal completed and are working as e
Slide 7: Cloudmed Update
7 Cloudmed Update1 On track to complete acquisition by the end of June, subject to remaining closing conditions Q1 top-line results ahead of Cloudmed’s plan, driven by cross-selling into existing base and new wins Company is making progress in launching new products to drive organic growth; st
Slide 8: Q1'22 Non-GAAP Results – Q/Q and Y/Y Comparison
8 Q1’22 Non-GAAP Results – Q/Q and Y/Y Comparison Note1: Adjusted cost of services, adjusted SG&A expense, and adjusted EBITDA are non-GAAP measures. A reconciliation of non-GAAP to GAAP measures is provided in the Appendix of this presentation. ($ in millions) Q1'22 Q4'21 Q1'21 Key change driver(s)
Slide 9: Additional Commentary
9 Additional Commentary Generated $30.9 million in cash from operations in Q1’22 - Cash balance declined $6.2 million from year-end 2021 due to tax payments of $21.5 million related to Q1 vesting of employee equity awards, $10.0 million for capital expenditures, and $4.4 million for debt repayment
Slide 10: Appendix
10 Appendix
Slide 11: Use of Non-GAAP Financial Measures
11 Use of Non-GAAP Financial Measures In order to provide a more comprehensive understanding of the information used by R1’s management team in financial and operational decision making, the Company supplements its GAAP consolidated financial statements with certain non-GAAP financial performance
Slide 12: Reconciliation of Non-GAAP Financial Measures
12 Reconciliation of Non-GAAP Financial Measures $ in millions Reconciliation of GAAP Net Income to Non-GAAP Adjusted EBITDA Reconciliation of GAAP SG&A to Non-GAAP SG&A Reconciliation of GAAP Cost of Services to Non-GAAP Cost of Services Note1: Other costs are comprised of strategic initiatives cos